Thalidomide with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of non-transplant eligible myeloma patients in England. In addition, bortezomib with an alkylating agent and a corticosteroid is recommended as an option for first-line treatment of non-transplant eligible patients who are intolerant to or contraindicated to thalidomide.
Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) have been published in the British Journal of Haematology. MUK one, a Phase II multicentre, open label, randomised trial aimed to identify the optimal starting dose of bendamustine when given in combination with thalidomide and dexamethasone in relapsed…
DetailsData from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) has been published in the British Journal of Haematology. The publication represents a major milestone for the CTN by marking the completion of its first trial. MUK one, a Phase II multicentre, open label, randomised trial aimed…
Details
Charity No: SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG